UCLA Researchers & Innovators
Industry & Investors
News & Events
About
Concierge
Search Results - immunotherapy
42
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
An Alternative T Cell Redirecting Bispecific Antibody Against Human Cytomegalovirus (UCLA Case No. 2024-198)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have created a novel T cell redirecting bispecific antibody (TRBA) for treatment of cytomegalovirus (CMV) infection. BACKGROUND: The human cytomegalovirus (CMV) has a seroprevalence of about 60% in the USA and nearly 100% of the population in some parts of the world....
Published: 11/15/2024
|
Inventor(s):
Otto Yang
Keywords(s):
Anti-CD3 antibodies
,
Bispecific antibodies
,
CD8 T cells
,
Human cytomegalovirus (CMV)
,
immunocompromised patients
,
Immunotherapy
,
Lymphocytes
,
T cell redirecting bispecific antibody (TRBA)
,
Transplant
,
Viral infection
Category(s):
Therapeutics > Infectious Diseases
,
Therapeutics > Immunology And
Immunotherapy
Methods To Predict the Efficacy of Neoadjuvant Anti-PD-1 Therapy in Resectable Oral-Cavity Squamous Cell Carcinoma and Target Post-Surgical Relapses (UCLA Case No. 2022-039)
UCLA researchers in the School of Medicine have developed a novel therapeutic strategy to improve prognosis of resectable head and neck cancer patients based on clinical studies. BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent cancer, ranked sixth among common epithelial malignancies worldwide. Over a third...
Published: 11/4/2024
|
Inventor(s):
Roger Lo
Keywords(s):
anti-PD-1
,
head and neck cancer
,
head and neck squamous cell carcinoma (HNSCC)
,
Immunotherapy
,
oral cavity squamous cell carcinoma (OCSCC)
,
resectable tumors
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And
Immunotherapy
Combination Cancer Therapy Methods and Agents (UCLA Case No. 2024-084)
UCLA researchers from the Department of Medicine, Pathology, & Laboratory Medicine and Molecular & Medical Pharmacology have identified a novel cell-based therapy that leads to enhanced
immunotherapy
efficacy and overcomes treatment resistance to immune checkpoint blockade in non-small cell lung cancer. BACKGROUND: Non-small cell lung cancer...
Published: 11/4/2024
|
Inventor(s):
Bin Liu
,
Steven Dubinett
Keywords(s):
anti-tumor immunity
,
cell-based therapy
,
Immune checkpoint blockade
,
Immunotherapy
,
non-small cell lung cancer
,
treatment resistance
,
Tumor microenvironment
,
Vaccines
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And
Immunotherapy
,
Therapeutics > Respiratory And Pulmonary
Interferon Activation Score Is a Biomarker for
Immunotherapy
in Malignant Glioma Patients (UCLA Case No. 2024-043)
UCLA researchers from the Department of Neurosurgery have characterized immune responses in malignant glioma patients receiving
immunotherapy
to develop a robust biomarker that will allow prediction of clinical outcomes following treatment. BACKGROUND: Malignant gliomas are the most common primary brain tumors in adults. No cures exist and most gliomas...
Published: 10/23/2024
|
Inventor(s):
Robert Prins
Keywords(s):
adjuvant therapy
,
Biomarker
,
Chemotherapy
,
Clinical Trial
,
dendritic cell vaccination
,
Glioblastoma
,
Glioma
,
immune response
,
Immunotherapy
,
interferon
,
malignant glioma
Category(s):
Diagnostic Markers > Immunology
,
Diagnostic Markers > Cancer
,
Therapeutics > Inflammation And Inflammatory Diseases
,
Therapeutics > Oncology
,
Therapeutics > CNS and Neurology
Affinity and Functional Based Screening of T Cell Receptor Repertoire Using Nanovials (Case No. 2024-042)
Summary: Researchers in the Department of Bioengineering at UCLA have developed a hydrogel platform that measures single T cell secretions, aiding in the definition of T cell receptor repertoires for functional
immunotherapy
applications. Background: T cell immunotherapies, namely T cell receptor (TCR) therapies, have emerged as promising candidates...
Published: 10/8/2024
|
Inventor(s):
Dino Di Carlo
,
Owen Witte
,
Doyeon Koo
,
Zhiyuan Mao
Keywords(s):
Cancer
Immunotherapy
,
CAR-T cell therapy
,
Flow Cytometry
,
hydrogel
,
Immunooncology
,
Immunotherapy
,
Peptide
,
single cell analysis
,
T Cell
,
T cell based therapy
Category(s):
Diagnostic Markers > Immunology
,
Life Science Research Tools > Screening Libraries
,
Therapeutics > Immunology And
Immunotherapy
Methods and Compositions for Treating Melanoma (UCLA Case No. 2021-324)
The Graeber Laboratory at UCLA discovered a novel mechanism for treating melanoma using ferroptosis, a type of programmed cell death, that shows promise against therapy resistance. BACKGROUND: Melanoma is a highly aggressive skin cancer that spreads throughout the body and can be fatal if left untreated. Therapies for melanoma range from
immunotherapy
...
Published: 7/10/2024
|
Inventor(s):
Thomas Graeber
Keywords(s):
Cancer
,
ferroptosis
,
Immunotherapy
,
MAPK signaling
,
Melanoma
,
Oncology
,
Skin
,
tumor resistance
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And
Immunotherapy
Engineered T Cells Capable of Simultaneous Tumor Targeting and Alteration of Tumor Microenvironment Through Vasculature Normalization (UCLA Case No. 2023-264)
UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have built a series of chimeric antigen receptor (CAR)-T cells that target different antigens and secrete different anti-angiogenic proteins. Additionally, researchers also constructed bispecific CARs that respond to tumor antigen and pro-angiogenic molecules. BACKGROUND:...
Published: 6/27/2024
|
Inventor(s):
Yvonne Chen
Keywords(s):
Cancer
,
Cancer
Immunotherapy
,
CAR-T cell therapy
,
immunosuppression
,
Immunosuppressive Drug
,
Immunotherapy
,
solid tumors
,
Tumor microenvironment
,
tumor vasculature
,
VEGF
Category(s):
Therapeutics > Oncology
Targeting Serotonin Transporter (SERT) for Cancer
Immunotherapy
(UCLA Case No. 2024-204)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have unveiled a novel therapeutic strategy utilizing SSRIs for solid cancer
immunotherapy
. BACKGROUND: Immunotherapy has become a highly effective method to combat cancer that enhances a patient’s immune system to attack tumors with high specificity. For instance,...
Published: 6/18/2024
|
Inventor(s):
Lili Yang
Keywords(s):
Cancer
,
Immune checkpoint blockade
,
immune checkpoint inhibitors
,
Immunotherapy
,
selective serotonin reuptake inhibitors (SSRIs)
,
serotonin
,
solid tumors
,
T Cell
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And
Immunotherapy
Strategies to Detect, Prevent and Reverse Acquired Resistance to Immune Checkpoint Blockade Therapy (UCLA Case No. 2024-085)
UCLA researchers in the Department of Medicine have uncovered novel mechanism of acquired resistance against immune checkpoint blockade therapy in melanoma patients. BACKGROUND: Immune checkpoint blockade (ICB) therapy is a type of cancer
immunotherapy
that targets immune system components in order to reactivate immune cells to combat tumor cells....
Published: 5/8/2024
|
Inventor(s):
Roger Lo
Keywords(s):
acquired resistance
,
Apoptosis
,
Cancer
,
Cancer
Immunotherapy
,
Immune checkpoint blockade
,
Immunotherapy
,
Melanoma
,
T Cell
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And
Immunotherapy
Novel Anti-mesothelin CAR for Use in Engineered Cell Therapies (UCLA Case No. 2023-281)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have developed a nanobody-based CAR T cell platform with increased stability and cross-immunogenicity between human and mouse antigens. BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy makes use of reengineered T cells to target and clear cancer cells....
Published: 6/28/2024
|
Inventor(s):
Yvonne Chen
Keywords(s):
Cancer
,
CAR-T cell platform
,
CAR-T cell therapy
,
cell engineering
,
Immunotherapy
,
Mesothelin
,
nanobody
,
Nanoparticle
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And
Immunotherapy
1
2
3
4
5